 |
市場調查報告書
商品編碼
1747535
卵巢（PCOS）治療市場（按藥物類別、分銷管道和地區）Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class, By Distribution Channel, By Region |
||||||
價格
簡介目錄
卵巢症候群 (PCOS) 治療市場預計在 2025 年達到 11.952 億美元，到 2032 年將達到 16.661 億美元，2025 年至 2032 年的複合年成長率為 4.86%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 11.952億美元 |
| 效能數據 | 從2020年到2024年 | 預測期 | 2025年至2032年 |
| 預測期：2025-2032年複合年成長率： | 4.86% | 2032年價值預測 | 16.661億美元 |
卵巢症候群 (PCOS) 是一種由於內分泌系統失調導致卵巢內形成充滿液體的小囊的疾病。它會影響患有 PCOS 的育齡女性。 PCOS 陽性女性更容易出現流產、妊娠期糖尿病、妊娠高血壓、妊娠毒血症和早產。此外，PCOS 女性還可能出現月經、雄性激素（性荷爾蒙）水平升高、毛髮過度生長、痤瘡和肥胖。
多囊性卵巢症候群 (PCOS) 女性更容易出現嚴重的健康問題，包括第 2 型糖尿病、高血壓、心血管疾病以及子宮癌。 PCOS 女性通常難以懷孕（不孕）。
市場動態
口服避孕藥的有效使用和產品價值的提高可能會在預測期內推動卵巢症候群 (PCOS) 治療市場的發展。例如，2022 年 8 月發表在 NCBI 上的一篇論文指出，在 PCOS 的治療中，口服避孕藥 (OC) 的主要作用機制是控制月經。這些藥物還可以透過降低睪固酮水平來減少多毛症和痤瘡。因此，口服避孕藥是卵巢症候群 (PCOS) 的主要治療方法。
此外，隨著人們對卵巢症候群 (PCOS) 治療新機制的認知不斷提高，預計將在預測期內推動市場成長。例如，中華醫學會婦產科分會於 2020 年 11 月發表的一項研究表明，電針 (EA) 干預透過調節脂質代謝調節劑 SREBP1 改善胰島素抗性 (IR)、粒線體功能障礙和氧化壓力，從而緩解大鼠的 PCOS 樣症狀。該研究結果揭示了電針在 PCOS 治療中的一種新型保護機制。
本研究的主要特點
- 本報告對全球卵巢症候群 (PCOS) 治療市場進行了詳細分析，並提供了預測期 2025-2032（以 2024 年為基準年）的市場規模和年複合成長率（CAGR%）。
- 它揭示了各個領域的潛在商機，並說明了該市場的一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 全球卵巢症候群 (PCOS) 治療市場的主要企業是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數列出的。
- 全球卵巢症候群 (PCOS) 治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過用於分析全球卵巢症候群 (PCOS) 治療市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 限制因素
- 市場吸引力分析
- 市場機會
- 流行病學
- 監管情景
- 產品發布
- 合併、收購和合作
- 主要進展
- 市場趨勢
- PEST分析
- 波特的分析
- 風險和副作用
- 主要市場參與者的新投資
- 管道分析
- 供應鏈分析
- 定價分析
- 品牌分析
4. 全球卵巢症候群 (PCOS) 治療市場-冠狀病毒 (COVID-19) 大流行的影響
- 經濟影響
- COVID-19流行病學
- 對臨床試驗的影響
5. 2020 年至 2032 年全球多卵巢症候群 (PCOS) 治療市場（依藥物類別）
- 口服避孕藥
- 胰島素增敏劑
- 抗憂鬱症
- 鳥氨酸脫羧酶抑制劑
- Aromatase抑制劑/SERM
- 利尿劑
6. 2020 年至 2032 年全球多卵巢症候群 (PCOS) 治療市場（依分銷管道）
- 醫院藥房
- 零售藥局
- 網路藥局
7. 2020 年至 2032 年全球多卵巢症候群 (PCOS) 治療市場（按地區）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第8章 競爭態勢
- Sanofi SA
- Amneal Pharmaceuticals, Inc.
- Laurus Labs Limited
- Zydus Pharmaceuticals, Inc.
- Prasco Laboratories
- Reddy's Laboratories
- Cadila Pharmaceuticals
- Novartis International AG
- Concordia Pharmaceuticals Inc.
- Covis Pharmaceuticals, Inc.
- Cardinal Health
- Aphena Pharma Solutions Tennessee, Inc.
- Mylan NV
- McKesson Corporation
- Teva Pharmaceutical Industries Ltd
- Lupin Pharmaceutical
- Sun Pharmaceutical Industries Ltd.
第9章 章節
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI1589
Polycystic Ovary Syndrome (PCOS) Treatment Market is expected to be USD 1,195.2 Mn in 2025 and is anticipated to reach USD 1,666.1 Mn in 2032 at a compound annual growth rate (CAGR) of 4.86% for the forecast period of 2025 to 2032
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1,195.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 4.86% | 2032 Value Projection: | USD 1,666.1 Mn |
Polycystic Ovarian Syndrome (PCOS) can be described as small sacs filled with fluid develop on the ovaries as a result of the endocrine system condition. Women with PCOS who are of childbearing age are affected. PCOS-positive women are more likely to experience miscarriage, gestational diabetes, pregnancy-induced hypertension, preeclampsia, and early birth. Moreover, women with PCOS may experience irregular menstrual cycles, elevated androgen (sex hormone) levels, excessive hair growth, acne, and obesity.
Women who have PCOS are more likely to develop serious health issues. These include type 2 diabetes, high blood pressure, heart and blood vessel problems, and uterine cancer. Women suffering from PCOS frequently struggle to conceive (fertility).
Market Dynamics
Effective use of oral contraceptives and increasing product value can drive the polycystic ovary syndrome (PCOS) treatment market over the forecast period. For instance, in August 2022, an article was published in the NCBI, according to which, for the treatment of PCOS, the major mechanism of action of oral contraceptives (OCs) is to control menstruation. These drugs also reduce hirsutism and acne by lowering testosterone levels. Thus, oral contraceptives are primary treatment for the polycystic ovary syndrome.
Moreover, rising awareness about novel mechanisms in the treatment of Polycystic Ovary Syndrome (PCOS) is anticipated to boost the growth of the market over the forecast period. For instance, according to research study published by Department of Obstetrics and Gynecology, China in November 2020, stated that the electroacupuncture (EA) intervention alleviated PCOS-like symptoms in rats by improving IR, mitochondrial dysfunction and oxidative stress through regulation of SREBP1, a regulator of lipid metabolism. The study findings illuminate the novel protective mechanisms of EA in the treatment of PCOS.
Key features of the study:
- This report provides in-depth analysis of the global Polycystic Ovary Syndrome (PCOS) Treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global Polycystic Ovary Syndrome (PCOS) Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Polycystic Ovary Syndrome (PCOS) Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Polycystic Ovary Syndrome (PCOS) Treatment Market
Market Segmentation
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Sanofi S.A.
- Amneal Pharmaceuticals, Inc.
- Laurus Labs Limited
- Zydus Pharmaceuticals, Inc.
- Prasco Laboratories
- Reddy's Laboratories
- Cadila Pharmaceuticals
- Novartis International AG
- Concordia Pharmaceuticals Inc.
- Covis Pharmaceuticals, Inc.
- Cardinal Health
- Aphena Pharma Solutions Tennessee, Inc.
- Mylan N.V.
- McKesson Corporation
- Teva Pharmaceutical Industries Ltd
- Lupin Pharmaceutical
- Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Epidemiology
- Regulatory Scenario
- Product Launches
- Merger, Acquisition, Collaborations
- Key Developments
- Market Trends
- PEST Analysis
- PORTER'S Analysis
- Risk and Adverse Effects
- New Investments by Major Market Players
- Pipeline Analysis
- Supply Chain Analysis
- Pricing Analysis
- Brand Analysis
4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Clinical Trials
5. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class, 2020 - 2032, (US$ Million)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral contraceptives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Insulin Sensitizing Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Anti- Depressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Ornithine Decarboxylase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Aromatase Inhibitors & SERMs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
6. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Distribution Channel, 2020 - 2032, (US$ Million)
- Introduction
- Market Share Analysis, 2025 and 2032(%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
7. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Region, 2020 - 2032, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032(%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amneal Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Laurus Labs Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zydus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Prasco Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cadila Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Concordia Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Covis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cardinal Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aphena Pharma Solutions Tennessee, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- McKesson Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lupin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
